, Singapore

Daily Markets Briefing: STI ends flat

Immediate resistance pegged at the 3300 mark.

OCBC Investment Research noted:

The mild pullback on Wall Street overnight and the weak Nikkei start (down 0.3% now) are likely to keep the local sentiment muted this morning.

Despite so, the STI has shown further signs of moderating its decline yesterday with a flat close, following a poor start to the day.

As such, the index could continue to consolidate around current levels today as it builds a base.

For now, we still peg the immediate resistance at the 3300 psychological obstacle, with the next resistance at the 3320 support-turned-resistance.

On the downside, the immediate base lies at the 3270 minor trough, followed by the next support at the 3240 key resistance-turned-support.
 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Top News

AI growth stalls as 78% cite weak data infrastructure
Confluent said firms are prioritising data streaming as they move AI projects from pilots into production.
Singapore emerges as key hub in Asia-Pacific’s next medtech wave
The city-state’s regulatory strength helps translate medical innovations into globally validated products.
Healthcare